
### [NCIT:C8932](http://purl.obolibrary.org/obo/NCIT_C8932)
**Label:** Stage 0 Colorectal Cancer AJCC v6 and v7

**Subclasses:** [NCIT:C5017](http://purl.obolibrary.org/obo/NCIT_C5017) (Stage 0 Rectosigmoid Cancer AJCC v6 and v7), [NCIT:C4853](http://purl.obolibrary.org/obo/NCIT_C4853) (Stage 0 Rectal Cancer AJCC v6 and v7), [NCIT:C4594](http://purl.obolibrary.org/obo/NCIT_C4594) (Cecum Carcinoma In Situ), [NCIT:C3638](http://purl.obolibrary.org/obo/NCIT_C3638) (Stage 0 Colon Cancer AJCC v6 and v7), 

**Class expressions from DL-Learner:**

- Thing 54.38%
- [NCIT:C90530](http://purl.obolibrary.org/obo/NCIT_C90530) (AJCC v7 Stage) 51.67%
- [NCIT:C90529](http://purl.obolibrary.org/obo/NCIT_C90529) (AJCC v6 Stage) 51.67%
- [NCIT:C28079](http://purl.obolibrary.org/obo/NCIT_C28079) (Grade 3) 51.67%
- [NCIT:C25785](http://purl.obolibrary.org/obo/NCIT_C25785) (KRAS Gene) 51.67%
- [NCIT:C18363](http://purl.obolibrary.org/obo/NCIT_C18363) (BRAF Gene) 51.67%
- [NCIT:C17567](http://purl.obolibrary.org/obo/NCIT_C17567) (APC Gene) 51.67%
- [NCIT:C17359](http://purl.obolibrary.org/obo/NCIT_C17359) (TP53 Gene) 51.67%
- [NCIT:C25784](http://purl.obolibrary.org/obo/NCIT_C25784) (RAS Family Gene) and (not ([NCIT:C25786](http://purl.obolibrary.org/obo/NCIT_C25786) (NRAS Gene))) 37.02%
- [NCIT:C25784](http://purl.obolibrary.org/obo/NCIT_C25784) (RAS Family Gene) and (not ([NCIT:C17060](http://purl.obolibrary.org/obo/NCIT_C17060) (HRAS Gene))) 37.02%
- [NCIT:C28051](http://purl.obolibrary.org/obo/NCIT_C28051) (Stage 0) 30.53%
- [NCIT:C25784](http://purl.obolibrary.org/obo/NCIT_C25784) (RAS Family Gene) 30.53%
- [NCIT:C18437](http://purl.obolibrary.org/obo/NCIT_C18437) (G Protein Gene) 30.53%
- [NCIT:C25784](http://purl.obolibrary.org/obo/NCIT_C25784) (RAS Family Gene) and (not ([NCIT:C40154](http://purl.obolibrary.org/obo/NCIT_C40154) (Endometrial Transitional Cell Carcinoma))) 30.53%
- [NCIT:C25784](http://purl.obolibrary.org/obo/NCIT_C25784) (RAS Family Gene) and (not ([NCIT:C40153](http://purl.obolibrary.org/obo/NCIT_C40153) (Endometrial Mixed Adenocarcinoma))) 30.53%


